MedWatch

Genmab rival will determine Darzalex's future against other cancer types

After last year's failure, Genmab's partner might be willing to give the drug Darzalex another chance against solid cancers. However, it depends on the results of a study from the rival Sanofi.

Jan van de Winkel, CEO of Genmab. | Foto: Ritzau Scanpix/Mik Eskestad

CEO in Genmab Jan van de Winkel keeps a close eye on Sanofi these days. The French drug group is testing isatuximab - a rival for Genmab's best-selling cancer drug Darzalex.

Sanofi's trials with isatuximab can be a determinant factor for Darzalex's future against solid cancers - tumors that occur in organs such as lungs and liver. Darzalex is already approved against multiple myeloma, which is a type of blood cancer.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier